Abstract
In this placebo controlled, randomised, double blind trial, pregnant women received from the 20th week of gestation onwards either 500 mg docosahexaenoic acid (DHA), 400 mg 5-methyl-tetra-hydro-folate (5-MTHF), or placebo, or a combination of 500 mg DHA and 400 mg 5-MTHF. The dietary supplements were well tolerated; the dropout rates did not differ significantly in the active arms of the study (10% to 19%) from that seen in the placebo group (13%). DHA supplementation resulted in significant enhancement of the contribution of DHA to maternal, placental and venous cord blood lipids.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Dietary Supplements
-
Docosahexaenoic Acids / administration & dosage
-
Docosahexaenoic Acids / blood
-
Double-Blind Method
-
Erythrocytes / chemistry
-
Fatty Acids, Omega-3 / administration & dosage*
-
Fatty Acids, Omega-3 / blood
-
Fatty Acids, Omega-3 / metabolism
-
Female
-
Fetal Blood / chemistry
-
Humans
-
Infant
-
Infant, Newborn
-
Lipid Metabolism*
-
Maternal Nutritional Physiological Phenomena*
-
Maternal-Fetal Exchange*
-
Placenta / metabolism
-
Pregnancy
-
Pregnancy Trimester, Second / blood
-
Pregnancy Trimester, Third / blood
-
Tetrahydrofolates / administration & dosage
-
Tetrahydrofolates / blood
Substances
-
Fatty Acids, Omega-3
-
Tetrahydrofolates
-
Docosahexaenoic Acids
-
5-methyltetrahydrofolate